Correlation Between Neurocrine Biosciences and Bristol Myers

Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Bristol Myers at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Bristol Myers into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurocrine Biosciences and Bristol Myers Squibb, you can compare the effects of market volatilities on Neurocrine Biosciences and Bristol Myers and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Bristol Myers. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Bristol Myers.

Diversification Opportunities for Neurocrine Biosciences and Bristol Myers

-0.25

Correlation Coefficient

Neurocrine Biosciences  Bristol Myers

Very good diversification

The 3 months correlation between Neurocrine and Bristol is -0.25. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Bristol Myers. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Bristol Myers go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Bristol Myers

Given the investment horizon of 90 days Neurocrine Biosciences is expected to under-perform the Bristol Myers. In addition to that, Neurocrine Biosciences is 1.76 times more volatile than Bristol Myers Squibb. It trades about -0.1 of its total potential returns per unit of risk. Bristol Myers Squibb is currently generating about 0.09 per unit of volatility. If you would invest  5,545  in Bristol Myers Squibb on December 30, 2024 and sell it today you would earn a total of  457.00  from holding Bristol Myers Squibb or generate 8.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Neurocrine Biosciences  vs.  Bristol Myers Squibb

Neurocrine Biosciences

Risk-Adjusted Performance

Very Weak

Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Bristol Myers Squibb

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Neurocrine Biosciences and Bristol Myers

The main advantage of trading using opposite Neurocrine Biosciences and Bristol Myers positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Bristol Myers can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will offset losses from the drop in Bristol Myers' long position.

The idea behind Neurocrine Biosciences and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.